Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell-Mediated T-Cell Responses.
Casper W F van EijckHassana El HaddaouiSongul KucukcelebiDisha VadgamaAmine FellahDana A M MustafaJoachim G J V AertsCasper H J van EijckMarcella WillemsenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
This study presents compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through rintatolimod. Rintatolimod may break immunologic tolerance by enhancing antitumor immunity through DC-mediated Th-cell responses. Furthermore, our findings lay the groundwork for investigating the potential synergy between TLR-3 activation and immune checkpoint inhibitor therapy to improve therapeutic outcomes. See related commentary by Martínez-Riaño et al., p. 3355.